Detail akcie AdaptimmTher Sp ADR online

Business Summary: Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Adaptimmune Therapeutics PLC - ADR revenues decreased 84% to $21M. Net loss totaled $77.9M vs. income of $21M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Clinical-stage biopharmaceutical segment loss totaling $76M vs. income of $19.4M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.01 to -$0.05.